Ontology highlight
ABSTRACT:
SUBMITTER: Handy CE
PROVIDER: S-EPMC5925432 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
Handy Catherine E CE Antonarakis Emmanuel S ES
Future oncology (London, England) 20171220 10
Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immu ...[more]